EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Liver cancer development driven by the AP-1/c-Jun~Fra-2 dimer through c-Myc

Latifa Bakiri iD, Sebastian C Hasenfuss, Ana Guío-Carrión iD, Martin K Thomsen iD, Peter Hasselblatt iD, Erwin F Wagner iD

Proceedings of the National Academy of Sciences · 30.04.2024 · 121 (18)

DOI: 10.1073/pnas.2404188121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 24.04.2024. Verfasst von Latifa Bakiri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Genes and Disease, Department of Laboratory Medicine, Medical University of Vienna, 1090, Vienna, Austria. Hauptthemen laut MEDLINE: Transcription Factor AP-1, Proto-Oncogene Proteins c-myc, Proto-Oncogene Proteins c-fos, Liver Neoplasms. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: EC | European Research Council (ERC), EC | Horizon 2020 Framework Programme (H2020).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death. HCC incidence is on the rise, while treatment options remain limited. Thus, a better understanding of the molecular pathways involved in HCC development has become a priority to guide future therapies. While previous studies implicated the Activator Protein-1 (AP-1) (Fos/Jun) transcription factor family members c-Fos and c-Jun in HCC formation, the contribution of Fos-related antigens (Fra-) 1 and 2 is unknown. Here, we show that hepatocyte-restricted expression of a single chain c-Jun~Fra-2 protein, which functionally mimics the c-Jun/Fra-2 AP-1 dimer, results in spontaneous HCC formation in c-Jun~Fra-2 hep mice. Several hallmarks of human HCC, such as cell cycle dysregulation and the expression of HCC markers are observed in liver tumors arising in c-Jun~Fra-2 hep mice. Tumorigenesis occurs in the context of mild inflammation, low-grade fibrosis, and Pparγ-driven dyslipidemia. Subsequent analyses revealed increased expression of c-Myc, evidently under direct regulation by AP-1 through a conserved distal 3′ enhancer. Importantly, c-Jun~Fra-2-induced tumors revert upon switching off transgene expression, suggesting oncogene addiction to the c-Jun~Fra-2 transgene. Tumors escaping reversion maintained c-Myc and c-Myc target gene expression, likely due to increased c-Fos. Interfering with c-Myc in established tumors using the Bromodomain and Extra-Terminal motif inhibitor JQ-1 diminished liver tumor growth in c-Jun~Fra-2 mutant mice. Thus, our data establish c-Jun~Fra-2 hep mice as a model to study liver tumorigenesis and identify the c-Jun/Fra-2-Myc interaction as a potential target to improve HCC patient stratification and/or therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcription Factor AP-1Proto-Oncogene Proteins c-mycProto-Oncogene Proteins c-fosLiver NeoplasmsProto-Oncogene Proteins c-junFos-Related Antigen-2Carcinoma, HepatocellularAnimalsMiceHumansHepatocytesProtein MultimerizationGene Expression Regulation, NeoplasticMice, TransgenicFos-Related Antigen 1

Stichwörter der Autor:innen

AP-1HCCc-Jun/Fra-2c-Mycmouse models

Substanzen

Transcription Factor AP-1Proto-Oncogene Proteins c-mycProto-Oncogene Proteins c-fosProto-Oncogene Proteins c-junFos-Related Antigen-2Fos-Related Antigen 1Myc protein, mouseFosl2 protein, mouse

Autor:innen und Institutionen

  • Laboratory Genes and Disease, Department of Laboratory Medicine, Medical University of Vienna, 1090, Vienna, Austria.
  • Genes, Development and Disease Group, National Cancer Research Centre, 28029, Madrid, Spain.
  • Department of Biomedicine, University of Aarhus, 8000, Aarhus, Denmark.
  • Department of Medicine II, University Hospital and Faculty of Medicine, 79106, Freiburg, Germany.
  • Laboratory Genes and Disease, Department of Dermatology, Medical University of Vienna, 1090, Vienna, Austria.

ORCID-Profile: Latifa Bakiri, Ana Guío-Carrión, Martin K Thomsen, Peter Hasselblatt, Erwin F Wagner

Förderung

  • EC | European Research Council (ERC)
  • EC | Horizon 2020 Framework Programme (H2020)

Zitieren

APA

Bakiri, L., Hasenfuss, S. C., Guío-Carrión, A., Thomsen, M. K., Hasselblatt, P., & Wagner, E. F. (2024). Liver cancer development driven by the AP-1/c-Jun~Fra-2 dimer through c-Myc. Proceedings of the National Academy of Sciences, 121(18). https://doi.org/10.1073/pnas.2404188121

Vancouver

Bakiri L, Hasenfuss SC, Guío-Carrión A, Thomsen MK, Hasselblatt P, Wagner EF. Liver cancer development driven by the AP-1/c-Jun~Fra-2 dimer through c-Myc. Proceedings of the National Academy of Sciences. 2024;121(18). doi:10.1073/pnas.2404188121

BibTeX
@article{Bakiri2024,
  author = {Bakiri, Latifa and Hasenfuss, Sebastian C and Guío-Carrión, Ana and Thomsen, Martin K and Hasselblatt, Peter and Wagner, Erwin F},
  title = {Liver cancer development driven by the AP-1/c-Jun~Fra-2 dimer through c-Myc},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  volume = {121},
  number = {18},
  doi = {10.1073/pnas.2404188121}
}
Kostenlos starten →